Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26471261 | 1.00 | LMNA (0.34) | LMNAHTTNCOA1NCOA3GAA | |
| SCHEMBL7657382 | 0.88 | CRBN (0.34) | LMNAHTTNCOA1NCOA3GAA | |
| SCHEMBL7165490 | 0.87 | LMNA (0.42) | LMNAKDM4ECRBNRAB9ACYP11B1 | |
| SCHEMBL22200929 | 0.87 | LMNA (0.42) | LMNAKDM4ECRBNRAB9ACYP11B1 | |
| SCHEMBL37106799 | 0.87 | LMNA (0.42) | LMNAKDM4ECRBNRAB9ACYP11B1 | |
| SCHEMBL26471064 | 0.85 | KDM4E (0.36) | LMNAKDM4ECRBNCYP11B1CYP11B2 | |
| SCHEMBL26470794 | 0.83 | KDM4E (0.33) | LMNAHTTNCOA1NCOA3GAA | |
| SCHEMBL26623041 | 0.80 | BRD3 (0.42) | LMNAKDM4ECYP11B1CYP11B2POLB | |
| SCHEMBL7654782 | 0.77 | KDM4E (0.34) | LMNAHTTNCOA1NCOA3GAA | |
| SCHEMBL24728401 | 0.76 | LMNA (0.43) | LMNAKDM4ECRBNRAB9ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5637770-A | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-10 | — | — | US | claimed |
| US-20230257392-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI HAOYUAN MEDCHEMEXPRESS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257392-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAI HAOYUAN MEDCHEMEXPRESS CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-6407115-B1 | ANTICARCINOGENIC AND ANTITUMOR AGENTS; SIDE EFFECT REDUCTION, WATER SOLUBILITY | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6337400-B1 | MULTISTAGE REACTION OF CYANOACETAMIDE WITH KETO ESTERS WITH CYCLIZATION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| EP-0897924-B1 | PROCESS FOR THE PREPARATION OF TETRAHYDRO-INDOLIZINES | DAIICHI SEIYAKU CO (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-6172230-B1 | Process for the preparation of tetrahydro-indolizines | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-0897924-A1 | PROCESS FOR THE PREPARATION OF TETRAHYDRO-INDOLIZINES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-02-24 | — | — | EP | disclosed |
| US-5834476-A | DERIVATIVE OF CAMPTOTHECIN, ANTITUMOR AGENT, ANTICARCINOGENIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5770605-A | Method for treating leukemia with a hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5658920-A | ANTITUMOR AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-08-19 | — | — | US | disclosed |
| US-5637770-A | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-10 | — | — | US | disclosed |
| EP-0495432-B1 | Hexa-cyclic compound | DAIICHI SEIYAKU CO (JP) | 1996-05-29 | — | — | EP | disclosed |
| EP-0495432-A1 | Hexa-cyclic compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257392-A1 | INTERMEDIATE FOR SYNTHESIZING CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | WEE1, WEE2, FAR1 | LMNA 522/4885HTT 3779/4885NCOA1 4660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.